Tumorigenesis and the angiogenic switch

Nature Reviews Cancer

Volumn 3, Issue 6, 2003, Pages 401-410

  Bergers, Gabriele ^a   Benjamin, Laura E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BATIMASTAT; BRAIN SPECIFIC ANGIOGENESIS INHIBITOR 1; CYCLOOXYGENASE 2; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERSTITIAL COLLAGENASE; SEMAXANIB; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANEUPLOIDY; ANGIOGENESIS; ANGIOGENIC SWITCH; ANIMAL CELL; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; DRUG EFFECT; GENE FUNCTION; GENE TARGETING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; DISEASE COURSE; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037967272     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1093     Document Type: Review

References (109)

1. Hahn, W. C. et al. Rules for making human tumor cells, N. Engl. J. Med. 341, 1593-603 (2002).
2. Duesberg, P. et al. How aneuploidy may cause cancer and genetic instability. Anticancer Res. 19, 4887-4906 (1999).
3. Pelengaris, S. et al. c-MYC: more than just a matter of life and death. Nature Rev. Cancer 2, 764-776 (2002).
4. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
5. Hanahan, D. et al. The hallmarks of cancer. Cell 100, 57-70 (2000).
6. Folkman, J. in Cancer Medicine (Holland, M.D. et al.) 2546 (BC Decker. Hamilton, Ontario, 2000).
7. Papetti, M. et al. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C497-C970 (2002).
8. Hlatky, L. et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl Cancer Inst. 94, 883-893 (2002). This important review discusses several misconceptions in the angiogenesis field. It specifically focuses on microvessel density and the information that can and cannot be gained from it.
9. Dor, Y. et al. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol. 280, C1367-C1374 (2001).
10. Kerbel, R. et al. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727-739 (2002). This is a recent and detailed review about antiangiogenic therapy.
11. Hanahan, D. et al. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
12. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389-395 (2000).
13. Dvorak, H. F. Tumors: wounds that do not head. Similanties between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986).
14. Benjamin, L. E. et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
15. Monkawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000 (2002).
16. Folberg, R. et al. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361-381 (2000).
17. McDonald, D. M. et al. Vasculogenic mimicry: how convincing, how novel, and how significant? Am. J. Pathol. 156, 383-388 (2000).
18. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001).
19. Rafli, S. et al. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 9, 631-641 (2002).
20. Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193, 1005-1014 (2001).
21. Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Med. 8, 841-849 (2002).
22. Pettersson, A. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99-115 (2000).
23. Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999). The is the first report showing that tumours do not always start as avascular lesions, but can also initially grow by co-opting existing blood vessels. The co-opted host vasculature does not immediately undergo angiogenesis to support the tumour - it first regresses before hypoxia-induced neovascularization is initiated.
24. Yancopoulos, G D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248 (2000).
25. Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738-4747 (1995).
26. Hirschi, K. K. et al. Pencytes in the microvasculature. Cardiovasc. Res. 32, 687 (1996).
27. Benjamin, L. E. et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598 (1998).
28. Benjamin, L. E. et al. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad Sci. USA 94, 8761-8766 (1997).
29. Papapetropoulos, A. et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest. 79, 213-223 (1999).
30. Adini, A. et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 62, 2749-2752 (2002).
31. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nature Rev Cancer 2, 795-803 (2002).
32. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med 7, 575-583 (2001).
33. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8, S62-S67 (2002).
34. Maxwell, P. H. et al. Activation of the HIF pathway in cancer: Curr. Opin. Genet. Dev. 11, 293-299 (2001).
35. Black, W. C. et al. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328, 1237-1243 (1993).
36. O'Reilly, M. S. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS. 79, 273-294 (1997).
37. O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
38. Joseph, I. B. et al. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 56, 3404-3408 (1996).
39. Subbaramaiah, K. et al. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24, 96-102 (2003).
40. Iniguez, M. A. et al. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol. Med. 9, 73-78 (2003).
41. Lieberman, R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev. 21, 297-309 (2002).
42. Hussain, T. et al. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 191, 125-135 (2003).
43. Chen, Y. J. et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol. Oncol. 88, 379-385 (2003).
44. Folkman, J. et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58 (1989).
45. Bergers, G. et al. Matrix metalloprotainase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737 (2000).
46. Coussens, L. M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis Genes Dev. 13, 1382-1397 (1999).
47. Bergers, G. et al. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42, 995 (1998).
48. Elson, D. A. et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 60, 1267-1275 (2000).
49. Inoue, M. et al. VEGF-A has a critical nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1, 193-202 (2002).
50. Rodriguez-Manzaneque, J. C. et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl Acad Sci. USA 98, 12485-12490 (2001).
51. Weidner, N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow J. Pathol. 184, 119-122 (1998).
52. Zabrenetzky, V. et al. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59, 191-195 (1994).
53. Weinstat-Saslow, D. L. et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54, 6504-6511 (1994).
54. Pelengaris, S. et al. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321-334 (2002).
55. Watnick, R. S. et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3, 219-231 (2003). This study strengthens the proposition that the angiogenic switch is a crucial step in tumour progression and that is determined by the ultimate balance in pro- and anti-angiogenic factors.
56. Vajkoczy, P. et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J. Clin. Invest. 109, 777-785 (2002).
57. Holash, J. et al. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF Oncogene 18, 5356-5362 (1999).
58. Shweiki, D. et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
59. Tomlinson, F. H. et al. The significance of atypia and histologic malignancy in pilocytic astrocytoma of the cerebellum: a clinicopathologic and flow cytometric study. J. Child. Neurol. 9, 301-310 (1994).
60. Brem, S. et al. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl Cancer Inst. 48, 347-356 (1972).
61. Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393 (2000).
62. Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306-314 (2000).
63. Filleur, S. et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. 15, 1373-1382 (2001).
64. Douglas, M. L. et al. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. BJU Int. 89, 591-595 (2002).
65. Yu, J. L. et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528 (2002).
66. Gee, M. S. et al. Hypoxia-mediated apoptosis from angiogenesis inhibition undedies tumor control by recombinant interleukin 12. Cancer Res. 59, 4882-4889 (1999).
67. Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349-4354 (2002).
68. Wang, J. H. et al. Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells Cancer 94, 2745-2755 (2002).
69. Zhang, X. S. et al Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacol. Sin. 22, 731-735 (2001).
70. Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613 (1996).
71. Stein, I. et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol. 15, 5363-5368 (1995).
72. Laderoute, K. R. et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6, 2941-2950 (2000).
73. Royds, J. A. et al. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol. Pathol. 51, 55-61 (1998).
74. Kwak, C. et al. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int. 89, 303-309 (2002).
75. Mukhopadhyay, D. et al. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression, Cancer Res. 55, 6161-6165 (1995).
76. Zhang, L. et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60, 3655-3661 (2000).
77. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha. Genes Dev. 14, 34-44 (2000).
78. Agani, F. et al. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res. 57, 4474-4477 (1997).
79. Holmgren, L. et al. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 17, 819-824 (1998).
80. Gautam, A. et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 9, 28-36 (2002).
81. Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
82. Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res, 60, 1878-1886 (2000).
83. Bergers, G. et al. Combining anti-angiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. CSH Symp. Quant Biol. 67, 293-300 (2002).
84. Bergers, G. et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812 (1999).
85. Shigematsu, K. et al. Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF. Eur J. Vasc. Endovasc. Surg. 14, 293-298 (1997).
86. Bergers, G. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature. J. Clin. Invest. 111, 1287-1295 (2003).
87. Cline, E. I. et al. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res. 62, 7143-7148 (2002).
88. Dancey, J. et al. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev. Drug Discov. 2, 296-313 (2003).
89. Hu, Y. L. et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl Cancer Inst. 93, 762-768 (2001).
90. Volpert, O. V. et al. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat. 36, 119-126 (1995).
91. Maeshima, Y. et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276, 15243-15248 (2001).
92. Kamphaus, G. D. et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275, 1209-1215 (2000).
93. Dameron, K. M. et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 Science 265, 1582-1584 (1994).
94. Lawler, J. et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am. J. Pathol. 159, 1949-1956 (2001).
95. Nishimori, H. et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis, Oncogene 15, 2145-2150 (1997).
96. Bian, J. et al. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol. 17, 6330-6338 (1997).
97. Brantley, D. M. et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011-7026 (2002).
98. Dohn, M. et al. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20, 6503-6515 (2001).
99. Cheng, N. et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 1, 2-11 (2002).
100. Sun, Y. et al. Human metalloproteinase-1 (collagenase-1) is a tumor suppressor protein p53 target gene. Ann. NY Acad. Sci. 878, 638-641 (1999).
101. Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. USA 97, 4052-4057 (2000).
102. Subbaramaiah, K. et al. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274, 10911-10915 (1999).
103. Pal, S. et al. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61, 6952-6957 (2001).
104. Moser, T Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl Acad. Sci. USA 96, 2811-2816 (1999).
105. Troyanovsky, B. et al. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell. Biol. 152, 1247-1254 (2001).
106. Yeh, P. J. et al. The antiangiogenic agent TNP470 requires p53 and p21 CIP/WAF for endothelial cell growth arrest. Proc. Natl Acad. Sci. USA 97, 12782-12787 (2000).
107. Sternlicht, M. D. et al. Matrix proteinases as emerging targets in anticancer therapy: status and prospects. ETT4, 609-633 (2000).
108. Fong, T. A. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99 (1999).
109. Laird, A. D. et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Res. 60, 4152-4160 (2000).